Company intelligence / Profile preview

Derozian

Ownership: Private
Development stage: Other

Overview

Dezima's lead candidate, TA-8995 (also known as DEZ‑001), demonstrated significant LDL-C reduction and HDL-C increase in phase 2b clinical trials for dyslipidemia. The drug showed up to a 48% reduction in LDL cholesterol and a substantial increase in HDL cholesterol, with most patients achieving stringent LDL-C targets when combined with statins. Common adverse events included nasopharyngitis and headache. The company was acquired by Amgen before advancing to phase III trials.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Mitsubishi Tanabe Pharma Corporation (in-license partner for TA‑8995)Forbion Capital Partners (lead investor prior to acquisition)

Beyond the preview

Go deeper on Derozian.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Derozian.

Explore the full profile